 *Febbraio 2016*

|  |
| --- |
| curriculum vitae11 |

|  |
| --- |
| Informazioni personali  |

|  |  |  |
| --- | --- | --- |
| Nome |  | **Giovanni cammarota** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

|  |
| --- |
| Luogo di Lavoro |
|  |  |  |
| Nome e indirizzo del datore di lavoro |  | Università Cattolica del Sacro Cuore (UCSC), Facoltà di Medicina e Chirurgia, Istituto di Medicina Interna e Geriatria, Policlinico Agostino Gemelli, Largo F. Vito 1, Roma |
|  |  |  |
| Tipo di impiego, |  | Professore Associato Confermato, Medicina Interna, Dirigente Medico |
|  principali mansioni e responsabilità |  | Responsabile di UOS “Malattie Infiammatorie Intestinali e Prevenzione Oncologica”, Polo Apparato digerente e Sistema Endocrino-Metabolico, Area di Gastroenterologia, U.O.C. di Medicina Interna e Gastroenterologia.  |

|  |
| --- |
| Principali note di carriera e formazione |
|  |  | Laurea in Medicina e Chirurgia presso l'UCSC di Roma |
|  |  |  |
|  |  | Specializzazione in Gastroenterologia ed Endoscopia Digestiva presso l'UCSC di Roma |
|  |  |  |
|  |  | Docente al Corso di Laurea di Medicina e Chirurgia presso l’Università Cattolica del Sacro Cuore di Roma, e, presso la stessa Università, Docente alle Scuole di Specializzazione in Gastroenterologia, Medicina Interna, Medicina di Emergenza-Urgenza, Microbiologia e Virologia, e ai Corsi di Dottorato in “Endoscopia digestiva sperimentale” e in “Scienze della nutrizione, del metabolismo, dell’invecchiamento e delle patologie di genere”Ha svolto ricerche in tema di fisiopatologia e clinica di patologie gastroenterologiche, inserite nel più ampio contesto della medicina interna. Tali ricerche sono state oggetto di pubblicazioni e comunicazioni scientifiche in campo internazionale e nazionale, oltreché motivo di collaborazione sul piano scientifico con importanti gruppi di ricerca nazionali ed internazionali, e di varie discipline specialistiche. In particolare, ha sviluppato ricerche in tema di *Helicobacter pylori*, infezioni croniche e rischio cardiovascolare, linfoma primitivo gastrico, celiachia, reflusso gastroesofageo, malattie infiammatorie croniche intestinali, endoscopia digestiva, microbiota gastrointestinale, trapianto di microbiota intestinale, *Clostridium difficile*. Relatore su invito a decine di congressi scientifici nazionali ed internazionali; docente, *faculty member* e direttore di corsi di aggiornamento.*Ad hoc reviewer* di numerose e prestigiose riviste scientifiche (JAMA, Lancet, Gastroenterology, American Journal of Gastroenterology, Endoscopy, Gastrointestinal Endoscopy, AP&T, etc) e di progetti di finanziamento internazionali. |

 **ELENCO DI ALCUNE DELLE PRINCIPALI PUBBLICAZIONI SCIENTIFICHE**

**Cammarota G**, Montalto M, Tursi A, Vecchio FM, Fedeli G, Gasbarrini G. Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma. LANCET 1995;345(8943):192.

**Cammarota G**, Tursi A, Montalto M, Papa A, Branca G, Vecchio FM, Renzi V, Verzì A, Armuzzi A, Pretolani S, Fedeli G, Gasbarrini G. Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H.pylori therapy**.** THE JOURNAL OF CLINICAL GASTROENTEROLOGY 1995; 21(2):118-122.

**Cammarota G**, Fedeli G, Tursi A, Corazza GR, Gasbarrini G. Coeliac disease and follicular gastritis. LANCET 1996;347(8996):268.

**Cammarota G**, Tursi A, Montalto M, Papa A, Veneto G, Bernardi S, Boari A, Colizzi V, Fedeli G, Gasbarrini G. Role of dental plaque in the transmission of Helicobacter pylori infection. THE JOURNAL OF CLINICAL GASTROENTEROLOGY 1996; 22(3):174-177.

**Cammarota G**, Tursi A, Papa A, Montalto M, Veneto G, Cuoco L, Fedeli G, Gasbarrini G. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1996;10(6):997-1000.

**Cammarota G**, Tursi A, Papa A, Fedeli G, Gasbarrini G. Sensitivity testing for Helicobacter pylori should be more widely available. BRITISH MEDICAL JOURNAL 1996;313:1079-1080.

**Cammarota G**, Tursi A, Papa A, MT.Voso, F.Serra, Fedeli G, Gasbarrini G. The growth of primary low-grade B-cell gastric lymphoma is sustained by Helicobacter pylori. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 1997;32(3):285-287.

**Cammarota G**, Tursi A, De Marinis L, Papa A, Valle D, Cuoco L, Cianci R, Fedeli G, Gasbarrini G. Gastric mucosa-associated lymphoid tissue in autoimmune thyroid diseases. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 1997;32(9):869-872.

**Cammarota G**, Papa A, Tursi A, Cuoco L, Fedeli G, Gasbarrini G. Pathogenesis of MALT lymphoma: an antigen-dependent process. GASTROENTEROLOGY 1997;113(5):1810.

**Cammarota G**, Tursi A, Cannizzaro O, Papa A, Cuoco L, Cianci R, Fedeli P, Fedeli G, Gasbarrini G. Regression of a primary gastric MALT-lymphoma with extensive antrum lesions by H.pylori eradication. ITALIAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 1997;29:361-364.

Pasceri V, **Cammarota G**, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A. Association of virulent Helicobacter pylori strains with ischemic heart disease. CIRCULATION 1998;97:1675-1679.

**Cammarota G**, Cannizzaro O, Tursi A, Papa A, Gasbarrini A, Cuoco L, Armuzzi A, Fedeli G, Gasbarrini G. One week therapy for H.pylori eradication: ranitidine bismuth citrate plus medium dose clarithromycin and tinidazole or amoxycillin. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1998;12:539-543.

**Cammarota G**, Pasceri V, Papa A, Cianci R, Gasbarrini A, Fedeli P, Cremonini F, Fedeli G, Maseri A, Gasbarrini G. Helicobacter pylori infection and ischaemic heart disease. ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 1998;30(suppl.3):S304-306.

**Cammarota G**, Papa A, Cianci R, Cannizzaro O, Armuzzi A, Gasbarrini A, Addolorato G, Gasbarrini G. 3-Day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 1999;11(3):247-50.

**Cammarota G**, Cianci R, Gasbarrini G. Eradication of Helicobacter pylori in routine clinical practice: doubts and uncertainties. HEPATO-GASTROENTEROLOGY 1999;46:312-315.

**Cammarota G**, Cianci R, Pirozzi G, Gasbarrini G. Minimal endoscopic aspects of gastric low-grade MALT lymphoma. HEPATO-GASTROENTEROLOGY 1999;446(29):2818-22.

**Cammarota G**, Cannizzaro O, Cianci R, Armuzzi A, Gasbarrini A, Pastorelli A, Gasbarrini G. Six-day or seven-day regimens with ranitidine bismuth citrate plus high dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. DIGESTIVE DISEASES AND SCIENCES 1999;44(12):2386-2389.

**Cammarota G**, Cannizzaro O, Cianci R, Gasbarrini A, Pirozzi G, Gasbarrini G. Six-day therapy with ranitidine bismuth citrate plus low dose clarithromycin and tinidazole to cure Helicobacter pylori infection. HEPATO-GASTROENTEROLOGY 2000;47(34):1176-1179.

**Cammarota G**, Cannizzaro O, Ojetti V, Cianci R, Pastorelli A, Armuzzi A, Gasbarrini A, Pirozzi G, Gasbarrini G. Five-day regimens containing ranitidine bismuth citrate plus high dose clarithromycin plus either amoxycillin or tinidazole are effective for the treatment of Helicobacter pylori infection. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2000;14(1):73-77.

**Cammarota G**, V.Pasceri, Gasbarrini A, Gasbarrini G. Helicobacter pylori is an aetiological agent in ischaemic heart disease: the case against. DIGESTIVE AND LIVER DISEASE 2000;32:65-68.

**Cammarota G**, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2000;14:1339-1343.

**Cammarota G**, Figura N, Cianci R, Pasceri V, Fedeli P, Lenzi GC, Gasbarrini G. Is there an antigenic mimicry between arteriosclerotic lesions and H.pylori antigens? CLINICAL BIOCHEMISTRY 2000;33(5):419-421.

**Cammarota G**, Cuoco L, Cianci R, Pandolfi F, Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. LANCET 2000;356:1495-1496.

**Cammarota G**, Larocca LM, D’Ugo D, Persiani R, Cianci R, Nocente R, Picciocchi A, Gasbarrini G. Sinchronous gastric adenocarcinoma and MALT-lymphoma in a patient with H.pylori infection. Could the two neoplasies share a common pathogenesis. HEPATO-GASTROENTEROLOGY 2001; 48(37):104-6.

**Cammarota G**, Pignataro F, Cuoco L, Cianci R, Carbone A, Gasbarrini G, Rapaccini GL. EUS in the diagnosis of collagenous colitis. GASTROINTESTINAL ENDOSCOPY 2001; 54(1):113-115.

**Cammarota G**, Cianci R, Grillo RL, Martini M, Di Campli C, Pompili M, Pignataro G, Cuoco L, De Lorenzo A, Gasbarrini G, Pandolfi F, Larocca LM. Relationship between gastric localization of hepatitis C virus and mucosa-associated lymphoid tissue in Helicobacter pylori infection. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 2002;37:1126-1132.

**Cammarota G**, Elia F, Cianci R, Galli J, Paolillo N, Montalto M, Gasbarrini G. Worsening of gastro-esophageal reflux symptoms in professional singers during performances. JOURNAL OF CLINICAL GASTROENTEROLOGY 2003; 36(5): 403-404.

**Cammarota G**, Galli J, Cianci R, De Corso E, Pasceri V, Palli D, Masala G, Buffon A, Gasbarrini A, Almadori G, Paludetti G, Gasbarrini G, Maurizi M. Association of laryngeal cancer with previous gastric resection. ANNALS OF SURGERY 2004;240(5):817-824.

**Cammarota G**, Cianci R, Cannizzaro O, Martino A, Fedeli P, Lecca PG, di Caro S, Cesaro P, Branca G, Gasbarrini G. High-dose versus low-dose clarithromycin in one-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. THE JOURNAL OF CLINICAL GASTROENTEROLOGY 2004;38(2):110-114.

**Cammarota G**, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week, both doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2004;19(7):789-795.

**Cammarota G**, Pirozzi, GA, Martino A, Zuccalà G, Cianci R, Cuoco L, Ojetti V, Landriscina M, Montalto M, Vecchio FM, Gasbarrini G, Gasbarrini A, Reliability of the "immersion technique" during routine upper GI endoscopy to detect abnormalities of duodenal villi in a population of dyspeptic subjects. GASTROINTESTINAL ENDOSCOPY 2004;60(2):223-228.

**Cammarota G**, Gasbarrini G**. *Helicobacter pylori* and gastro-oesophageal reflux disease: Information on underlying pathology is not given. BRITISH MEDICAL JOURNAL (BMJ)** 2004;329:402.

**Cammarota G**, Martino A, Pirozzi G, Cianci R, Cuoco L, Cremonini F, Ometti V, Montalto M, Vecchio FM, Gasbarrini A, Gasbarrini G. Direct visualisation of intestinal villi by high-resolution, high-magnification upper GI endoscopy. A validation study. GASTROINTESTINAL ENDOSCOPY 2004;60(5):732-8.

**Cammarota G**, Certo M. Images in clinical medicine. Corkscrew esophagus. The NEW ENGLAND JOURNAL of MEDICINE 2005;352(8):816.

**Cammarota G**, Martino A, Di Caro S, Cianci R, Lecca PG, Vecchio FM, Gasbarrini G. High-resolution magnifying upper endoscopy in a patient with patchy celiac disease. DIGESTIVE DISEASES AND SCIENCES 2005; 50(3):601-604.

**Cammarota G**, Gasbarrini A, Gasbarrini G. No more biopsy in the diagnostic work-up of celiac disease. GASTROINTESTINAL ENDOSCOPY 2005;62(1):119-21.

**Cammarota G**, Cianci R, Gasbarrini G. High-resolution magnifying video-endoscopy in primary intestinal lymphangiectasia: a new role for endoscopy? ENDOSCOPY 2005;37(6):607.

**Cammarota G**, Fedeli P, Bianchi A, Cianci R, Martino A, Fedeli G, Gasbarrini G. Regression of EI2-stage low-grade gastric MALT-Lymphoma after H pylori eradication. HEPATOGASTROENTEROLOGY 2005; 52(63):975-7.

**Cammarota G**, Cesaro P, Martino A, Zuccalà G, Cianci R, Nista E, Larocca LM, Vecchio FM, Gasbarrini A, Gasbarrini G. High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic approach in diagnosing coeliac disease. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2006; 23(1):61-69.

**Cammarota G**, Galli J, Agostino S, De Corso E, Rigante M, Cianci R, Cesaro P, Nista EC, Candelli M, Gasbarrini A, Gasbarrini G. Accuracy of laryngeal examination during upper gastrointestinal endoscopy for pre-malignancy screening: prospective study in patients with and without reflux symptoms. ENDOSCOPY 2006; 38:376-381.

**Cammarota G,** Schinzari G, Larocca LM, Gasbarrini G, Barone C. Duodenal metastasis from a primary angiosarcoma of the colon. GASTROINTESTINAL ENDOSCOPY 2006;63(2):330.

**Cammarota G**, Agostino S, Rigante M, Cesaro P, Parrilla C, La Mura R, Gasbarrini G, Galli J. Preliminary laryngeal examination during magnifying upper gastrointestinal video endoscopy in two patients with reflux symptoms. ENDOSCOPY 2006;38(3):287.

**Cammarota G**, Cesaro P, Gasbarrini G. A higher diagnosi profile is possibile for microscopic colitis. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2006;24(3):561.

**Cammarota G**, Cuoco L, Cesaro P, Santoro L, Cazzato A, Montalto M, La Mura R, Larocca LM, Vecchio FM, Salvagnini M, Gasbarrini G. A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study. ENDOSCOPY 2007; 39:46-51.

**Cammarota G,** Masala G, Cianci R, Palli D, Capaccio P, Schindler A, Cuoco L, Galli J, Ierardi E, Cannizzaro O, Caselli M, Dore MP, Bendinelli B, Gasbarrini G. Reflux symptoms in professional opera choristers. GASTROENTEROLOGY 2007;132(3):890-8. + COVER

**Cammarota G**, Cuoco L, Gasbarrini G. Reply to K. Rostami et al.: Endoscopy and small-bowel biopsy in celiac disease: indications and implications. ENDOSCOPY 2007;39:574.

**Cammarota G**, Cesaro P, La Mura R, Martino A, Cazzato, A. Miele L, Lupascu A, Vecchio FM, Larocca LM, Grieco A, Gasbarrini G. Role of the “immersion technique” in diagnosing celiac disease with villous atrophy limited to the duodenal bulb. THE JOURNAL OF CLINICAL GASTROENTEROLOGY 2007;41(6):571-575.

**Cammarota G**, Cesaro P, Cazzato A, Fedeli P, Riccioni ME, Sparano L, Vitale G, Costamagna G, Gasbarrini G, Larocca LM. Hydrogen peroxide-related colitis (previously known as “pseudolipomatosis”): report of an epidemic pattern of case series. ENDOSCOPY 2007;39:916-919.

**CammarotaG**, Larocca LM. Reply to dr. Souza et al: Intestinal pseudolipomatosis and electrolyzed acid water for disinfecting colonscope. ENDOSCOPY 2008;40:621.

 **Cammarota G**, Gasbarrini G. Reply to dr. Marchese M et al : Stress-related esophagopharyngeal reflux during warm-up exercises in a singer. GASTROENTEROLOGY. 2008;134(7):2193-2194.

**Cammarota G**, Cesaro P, Cazzato A, Fedeli P, Sparano L, Vecchio FM, Larocca LM, Gasbarrini G. Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease. GASTROINTESTINAL ENDOSCOPY 2008;68(2):352-357.

**Cammarota G**, Fedeli P, Gasbarrini A. Emerging technologies in upper gastrointestinal endoscopy and celiac disease. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY 2009;6(1):47-56.

**Cammarota G**, Cesaro P, Cazzato A, Cianci R, Fedeli P, Ojetti V, Certo M, Sparano L, Giovannini S, Larocca LM, Vecchio FM, Gasbarrini G. The water immersion technique is easy to learn for routine use during EGD for duodenal villous evaluation: a single centre 2-year experience. THE JOURNAL OF CLINICAL GASTROENTEROLOGY 2009;43:244–248.

**Cammarota G**, Piscaglia A. Free peritoneal gas accumulation due to pneumatosis coli following diagnostic gastrointestinal endoscopy. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7(8):A18.

**Cammarota G**, Cazzato A, Genovese O, Pantanella A, Ianiro G, Giorgio V, Montalto M, Vecchio FM, Larocca LM, Gasbarrini G, Fundarò C. Water immersion technique during standard upper endoscopy may be useful to drive the biopsy sampling of duodenal mucosa in children with celiac disease. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 2009;49:411-415.

**Cammarota G**, Masala G, Cianci R, Palli D, Bendinelli B, Galli J, Pandolfi F, Gasbarrini A, Landolfi R. Reflux symptoms in wind instrument players. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2010; 31:593–600.

**Cammarota G**, Branca G, Ardito F, Sanguinetti M, Ianiro G, Cianci R, Torelli R, Masala G, Gasbarrini A, Fadda G, Landolfi R, Gasbarrini G. Biofilm demolition and antibiotic treatment to eradicate resistant *Helicobacter pylori*: A clinical trial. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:817–820.

**Cammarota G**, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2012;36:222-230.

**Cammarota G**, Ianiro G, Sparano L, La Mura R, Ricci R, Larocca LM, Landolfi R, Gasbarrini A. Image-enhanced endoscopy with i-scan technology for the evaluation of duodenal villous pattern. DIGESTIVE DISEASES AND SCIENCES 2013;58:1287-1292.

**Cammarota G**, Ianiro G, Gasbarrini A. [Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review.](http://www.ncbi.nlm.nih.gov/pubmed/24440934) JOURNAL OF CLINICAL GASTROENTEROLOGY; 2014;48:693-702.

**Cammarota G**, Ianiro G, Gasbarrini A, Masucci L, Sanguinetti M. [Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy.](http://www.ncbi.nlm.nih.gov/pubmed/24457126) DIGESTIVE AND LIVER DISEASE 2014;46(5):475.

**Cammarota G**, Ianiro G, Bibbò S, Gasbarrini A. [Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?](http://www.ncbi.nlm.nih.gov/pubmed/24664520) INTERNAL AND EMERGENCY MEDICINE 2014;9(4):365-373.

**Cammarota G**, Ianiro G, Bibbò S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. [Culture-guided treatment approach for Helicobacter pylori infection: review of the literature.](http://www.ncbi.nlm.nih.gov/pubmed/24833850) WORLD JOURNAL OF GASTROENTEROLOGY 2014;20(18):5205-5211.

**Cammarota G**, Ianiro G, Bibbò S, Gasbarrini A. [Letter: telmisartan associated enteropathy - is there any class effect? Authors' reply.](http://www.ncbi.nlm.nih.gov/pubmed/25103354) ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2014;40(5):570.

**Cammarota G**, Ianiro G, Bibbò S, Gasbarrini A. [Fecal microbiota transplantation: a new old kid on the block for the management of gut microbiota-related disease.](http://www.ncbi.nlm.nih.gov/pubmed/25291136) JOURNAL OF CLINICAL GASTROENTEROLOGY 2014;48(suppl 1):S80-84.

**Cammarota G**, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. [The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy.](http://www.ncbi.nlm.nih.gov/pubmed/25561343) PHARMACOLOGY &THERAPEUTICS 2015;149:191-212.

**Cammarota G**, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. [Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.](http://www.ncbi.nlm.nih.gov/pubmed/25728808) ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 2015;41: 835-843

**Cammarota G**, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. ANNALS OF INTERNAL MEDICINE 2015; 163:487-488

**Cammarota G**, Pecere S, Ianiro G, Masucci L, Currò D. Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Dig Dis 2016;34:279-85.